Clinical trial
Neoadjuvant Pembrolizumab in High-risk Thyroid Cancers
NCT05852223 is registered in ClinicalTrials.gov with Istituti Clinici Scientifici Maugeri SpA as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Neoadjuvant Pembrolizumab in High-risk Thyroid Cancers
- Lead sponsor
- Istituti Clinici Scientifici Maugeri SpA
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- December 20, 2024
- Completion date
- November 30, 2026
- Enrollment
- 25 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
differentiated thyroid cancer